TDMS No. 20310 - 01

Route: GAVAGE

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 11:52:21

First Dose M/F: NA / 11/18/04

Date Report Requested: 07/22/2009

Lab: NCTR

C Number: C20310C

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lock Date: 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Treatment Groups: Include 612 Vehicle 6 mo F Include 615 AZT 120 6 mo F

Study Gender: Female

TDMSE Version: 2.1.0

Route: GAVAGE

Test Type: 26-39 WEEKS

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Date Report Requested: 07/22/2009

Time Report Requested: 11:52:21 First Dose M/F: NA / 11/18/04

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F
Disposition Summary		
Animals Initially in Study	27	26
Early Deaths		
Moribund Sacrifice	1	
Natural Death Survivors	1	
Moribund Sacrifice	1	
Terminal Sacrifice	24	26
Animals Examined Microscopically	27	26
ALIMENTARY SYSTEM		
Esophagus	(23)	(25)
Adventitia, Foreign Body	1	
Adventitia, Necrosis	1 [2.0]	
Gallbladder	(24)	(25)
Intestine Large, Cecum	(26)	(26)
Hyperplasia, Lymphoid	(00)	2 [2.0]
Intestine Large, Rectum	(26)	(26)
Intestine Small, Ileum Liver	(26) (26)	(26) (26)
Infiltration Cellular, Lymphocyte	(26)	1 [2.0]
Inflammation, Chronic Active	3 [1.0]	2 [1.0]
Tension Lipidosis	1 [1.0]	3 [2.0]
Vacuolization Cytoplasmic	1 [1.0]	1 [1.0]
Pancreas	(26)	(26)
Infiltration Cellular, Lymphocyte	, ,	1 [1.0]
Inflammation, Chronic Active		1 [1.0]
Salivary Glands	(26)	(26)
Infiltration Cellular, Lymphocyte	14 [1.1]	7 [1.1]
Stomach, Glandular	(26)	(26)
CARDIOVASCULAR SYSTEM		
Heart	(26)	(26)
Cardiomyopathy	1 [1.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS) CAS Number: 30516-87-1

Time Report Requested: 11:52:21 First Dose M/F: NA / 11/18/04

Date Report Requested: 07/22/2009

Lab: NCTR

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F	
Pericardium, Inflammation, Chronic Pericardium, Inflammation, Chronic Active	1 [3.0]	1 [2.0]	
Pericardium, Mineralization		1 [3.0]	
ENDOCRINE SYSTEM			-
Adrenal Cortex Accessory Adrenal Cortical Nodule Vacuolization Cytoplasmic Subcapsular, Hyperplasia Adrenal Medulla Parathyroid Gland Infiltration Cellular, Lymphocyte Pituitary Gland Thyroid Gland Cyst Infiltration Cellular, Lymphocyte	(26) 1 2 [2.0] 23 [1.0] (26) (22) 1 [1.0] (26) (26) (26) 1 [2.0] 1 [2.0]	(26) 1 24 [1.0] (26) (21) (26) (25) 1 [1.0]	
GENERAL BODY SYSTEM			
Tissue NOS Abscess	(0)	(1) 1 [4.0]	
GENITAL SYSTEM			
Ovary Cyst Uterus Endometrium, Hyperplasia, Cystic Lumen, Dilatation Vagina	(26) (26) 1 [2.0] 2 [1.5] (27)	(26) 1 [2.0] (26) 1 [1.0] 2 [1.5] (26)	
HEMATOPOIETIC SYSTEM			
Bone Marrow Myeloid Cell, Hyperplasia Lymph Node	(26) 3 [2.7] (3)	(26) 2 [3.0] (1)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

TDMS No. 20310 - 01

Route: GAVAGE

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS) CAS Number: 30516-87-1

Time Report Requested: 11:52:21 First Dose M/F: NA / 11/18/04

Date Report Requested: 07/22/2009

Lab: NCTR

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F
Mediastinal, Hyperplasia, Lymphoid Mediastinal, Infiltration Cellular, Plasma Cell	2 [4.0] 1 [4.0]	
Lymph Node, Mandibular Hyperplasia, Lymphoid Lymph Node, Mesenteric Hyperplasia, Lymphoid Spleen Depletion Lymphoid Hematopoietic Cell Proliferation Hyperplasia, Lymphoid Thymus Hyperplasia, Lymphoid Hyperplasia, Plasma Cell Necrosis Adventitia, Inflammation, Chronic Epithelial Cell, Hyperplasia	(26) 3 [1.3] (24) 7 [1.6] (26) 1 [3.0] 3 [3.7] (26) 3 [2.3] 1 [3.0] 1 [3.0] 1 [4.0] 1 [1.0]	(25) 2 [1.5] (25) 11 [1.4] (26) 2 [3.5] 2 [3.5] (26) 2 [2.0]
INTEGUMENTARY SYSTEM Mammary Gland Skin	(24) (26)	(24) (26)
MUSCULOSKELETAL SYSTEM	(20)	(20)
None		
NERVOUS SYSTEM		
Brain, Cerebrum Cyst Epithelial Inclusion	(26) 1	(26)
RESPIRATORY SYSTEM		
Lung Abscess	(26) 2 [4.0]	(26)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active	1 [1.0]	1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

TDMS No. 20310 - 01

Route: GAVAGE

Test Type: 26-39 WEEKS

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 11:52:21 First Dose M/F: NA / 11/18/04

Date Report Requested: 07/22/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F
Mediastinum, Inflammation, Chronic Active		1 [2.0]
Mediastinum, Mineralization Mediastinum, Necrosis	1 [4.0]	1 [4.0]
SPECIAL SENSES SYSTEM		
Harderian Gland Infiltration Cellular, Lymphocyte	(26) 1 [1.0]	(26)
URINARY SYSTEM		
Kidney Infiltration Cellular, Lymphocyte	(26) 8 [1.1]	(26) 3 [1.0]
Inflammation, Chronic Active Urinary Bladder Infiltration Cellular, Lymphocyte	1 [1.0] (26) 3 [1.0]	(26) 1 [1.0]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)